Question explored with the scientific record
Conversation so far
- 1 bioidentical hormones pros and cons
- 2 Is there strong evidence that bioidentical hormones work better than standard HT?
- 3 Is there any safety data for estradiol
- 4 What endometrial cancer or bleeding risks come with bioidentical progesterone?
- 5 Are there better-proven progesterone alternatives (IUD vs oral) for safety?
Answered on this page ↓
Are there better-proven progesterone alternatives (IUD vs oral) for safety?
The short version: the LNG-IUS beats oral progesterone on endometrial protection, but the breast cancer signal is real and the long-term safety data is thin.
The levonorgestrel-releasing intrauterine system (LNG-IUS) delivers progestin directly to the uterus, so a much lower dose reaches the rest of the body. That local delivery is the key difference. The Finnish registry study of over 17,000 women found the LNG-IUS cut endometrial cancer risk by more than half: 37 observed cases versus 80 expected, a standardized incidence ratio of 0.46 [1]. A systematic review of 11 studies confirmed the LNG-IUS prevents endometrial hyperplasia at least as well as oral, transdermal, or vaginal progesterone in women on estrogen therapy [4]. Meta-analysis data puts regression rates for complex hyperplasia at about 92% with the LNG-IUS versus 66% with oral progestogens [3].
But the same Finnish study found a breast cancer signal that cannot be ignored. Women using the LNG-IUS had 1,542 breast cancers versus 1,292 expected, a 19% increase [1]. That is a standardized incidence ratio of 1.19, with a tight confidence interval that makes it unlikely to be noise. The review evidence from 2011 found no significant difference in breast cancer incidence between LNG-IUS and oral progestogen users [2], but that was a smaller analysis and the Finnish registry is the larger, harder endpoint.
| Outcome | LNG-IUS | Oral progestogen | What the numbers show |
|---|---|---|---|
| Endometrial cancer risk | SIR 0.46 (37 vs 80 expected) [1] | Not directly compared in this retrieval | LNG-IUS cuts risk by more than half |
| Breast cancer risk | SIR 1.19 (1542 vs 1292 expected) [1] | Not directly compared in this retrieval | LNG-IUS associated with 19% increase |
| Complex hyperplasia regression | ~92% at 6-12 months [3] | ~66% [3] | LNG-IUS clearly superior |
| Ovarian cancer risk | SIR 0.60 (59 vs 99 expected) [1] | Not directly compared | LNG-IUS reduces risk |
The bleeding pattern is different too. The LNG-IUS produces amenorrhea in about 83% of women after 12 months, while cyclic oral progestin regimens cause predictable withdrawal bleeding averaging 6 days per month [4]. For women who want lighter or no periods, that is a meaningful difference.
What this retrieval does not settle: no study here directly compares LNG-IUS against oral bioidentical progesterone on long-term breast cancer rates. The Finnish registry used the synthetic progestin levonorgestrel, not bioidentical progesterone. The breast cancer signal may be specific to the synthetic molecule, or it may be a progestin-class effect. The evidence simply does not answer that.
My call: the LNG-IUS is clearly better than oral progestogens for endometrial protection and bleeding control, but carries a documented breast cancer risk that must be weighed. Confidence: moderate for endometrial outcomes, low for the breast cancer comparison against oral bioidentical progesterone specifically.
Sources used 4
-
Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland
This study investigates the association between the use of the levonorgestrel-releasing intrauterine system and cancer incidence in Finnish women, revealing a protective effect against endometrial, ovarian, pancreatic, and lung cancers, while indicating an increased risk for bre…
DOI: 10.1097/AOG.0000000000000356 -
Alternative regimens for endometrial protection – where are we now?
This study reviews the effectiveness and safety of various progestogens in hormone replacement therapy (HRT) for menopausal women, highlighting the advantages of using the levonorgestrel intrauterine system (LNG-IUS) and natural progesterone over traditional oral progestogens.
DOI: 10.3109/13697137.2011.635434 -
Should the Mirena intrauterine system be offered (unless contraindicated) to women presenting with postmenopausal bleeding at the time of endometrial sampling?
This narrative review evaluates the levonorgestrel-releasing intrauterine system (LNG-IUS) in postmenopausal bleeding and endometrial hyperplasia or carcinoma, finding that it suppresses proliferation, yields high regression rates, and is not required for isolated atrophic bleed…
DOI: 10.5348/100236z08ng2026rv -
Benefits of Levonorgestrel Intrauterine Device Use vs. Oral or Transdermal Progesterone for Postmenopausal Women Using Estrogen Containing Hormone Therapy
A systematic review of 11 studies found levonorgestrel intrauterine devices prevent endometrial hyperplasia at least as effectively as oral, transdermal, or vaginal progesterone in perimenopausal and postmenopausal women using estrogen replacement therapy.
DOI: 10.24926/iip.v10i3.2002